News
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
“We are thrilled to announce the initiation of our global Phase 3 DEEp Program with our first ... For such statements, Longboard claims the protection of the Private Securities Litigation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback